Lewy body pathology modifies risk factors for cerebral amyloid angiopathy when comorbid with Alzheimer's disease pathology
Alzheimer's & Dementia · 2024-04 · 20 (4) · 2564-2574
DOI: 10.1002/alz.13704 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 14.02.2024. Verfasst von Jagan A Pillai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Cerebral Amyloid Angiopathy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, National Institute on Aging.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Cerebral amyloid angiopathy (CAA) often accompanies dementia‐associated pathologies and is important in the context of anti‐amyloid monoclonal therapies and risk of hemorrhage. METHODS We conducted a retrospective neuropathology‐confirmed study of 2384 participants in the National Alzheimer Coordinating Center cohort (Alzheimer's disease [AD], n = 1175; Lewy body pathology [LBP], n = 316; and mixed AD and LBP [AD‐LBP], n = 893). We used logistic regression to evaluate age, sex, education, APOE ε4 , neuritic plaques, and neurofibrillary tangles (NFTs) in CAA risk. RESULTS APOE ε4 increased CAA risk in all three groups, while younger age and higher NFT stages increased risk in AD and AD‐LBP. In AD‐LBP, male sex and lower education were additional risk factors. The odds of APOE ε4 carrier homozygosity related to CAA was higher in LBP (25.69) and AD‐LBP (9.50) than AD (3.17). DISCUSSION AD and LBPs modify risk factors for CAA and should be considered in reviewing the risk of CAA. Highlights Lewy body pathology modifies risk factors for cerebral amyloid angiopathy (CAA) when present along with Alzheimer's disease (AD) neuropathology. In the context of anti‐amyloid monoclonal therapies and their associated risks for hemorrhage, the risk of underlying CAA in mixed dementia with Lewy body pathology needs to be considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio, USA.
- Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Neurology, Cleveland Clinic, Cleveland, Ohio, USA.
- Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington, USA.
Förderung
- NIA NIH HHS
- NINDS NIH HHS
- National Institute on Aging
- Nancy and Buster Alvord Endowment
- National Association for Colitis and Crohn's Disease
Zitieren
APA
Pillai, J. A., Bena, J., Tousi, B., Rothenberg, K., Keene, C. D., & Leverenz, J. B. (2024). Lewy body pathology modifies risk factors for cerebral amyloid angiopathy when comorbid with Alzheimer's disease pathology. Alzheimer's & Dementia, 20(4), 2564-2574. https://doi.org/10.1002/alz.13704
Vancouver
Pillai JA, Bena J, Tousi B, Rothenberg K, Keene CD, Leverenz JB. Lewy body pathology modifies risk factors for cerebral amyloid angiopathy when comorbid with Alzheimer's disease pathology. Alzheimer's & Dementia. 2024;20(4):2564-2574. doi:10.1002/alz.13704
BibTeX
@article{Pillai2024,
author = {Pillai, Jagan A and Bena, James and Tousi, Babak and Rothenberg, Kasia and Keene, C Dirk and Leverenz, James B},
title = {Lewy body pathology modifies risk factors for cerebral amyloid angiopathy when comorbid with Alzheimer's disease pathology},
journal = {Alzheimer's & Dementia},
year = {2024},
volume = {20},
number = {4},
pages = {2564--2574},
doi = {10.1002/alz.13704}
}
EUVIMED